We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement

Agilent Completes Acquisition of Seahorse Bioscience


Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Agilent Completes Acquisition of Seahorse Bioscience"

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Read time:
 

Seahorse's leading technology enables researchers to better understand cell health, function and signaling, and how the cell may be impacted by the introduction of a specific drug, by providing real-time kinetics to unlock essential cellular bioenergetics data.

Agilent acquired Seahorse Bioscience because its unique technology complements Agilent's leading separations and mass spectrometry solutions, in particular for metabolomics and disease research in pharma.

Scientists use Seahorse Bioscience's proprietary XF Technology to research the role of cell metabolism in neurodegeneration, aging, cancer, cardiovascular disease, cell physiology, toxicology and hepatobiology, immunology, infectious diseases, mitochondrial diseases, model organisms, obesity, diabetes, metabolic disorders, screening and translational medicine.

With the completion of the acquisition, most of the 200 employees who were with Seahorse are now part of the Mass Spectrometry Division of Agilent's Life Sciences and Applied Markets Group.

Advertisement